Multicellular living organisms and unmodified parts thereof and – Method of using a transgenic nonhuman animal to manufacture...
Reexamination Certificate
2007-11-13
2007-11-13
Li, Q. Janice (Department: 1633)
Multicellular living organisms and unmodified parts thereof and
Method of using a transgenic nonhuman animal to manufacture...
C800S004000, C800S005000, C800S021000
Reexamination Certificate
active
11143737
ABSTRACT:
The specification provides methods of preparing high-affinity antibodies to a macrophage migration inhibitory factor (MIF) in animals in which the MIF gene has been homozygously knocked-out (MIF−/−). Also provided are methods of preparing hybridomas which produce the anti-MIF antibodies, methods of administering the antibodies to treat inflammatory or cancerous conditions and/or diseases modulated by MIF, as well as compositions comprising said high-affinity anti-MIF antibodies.
REFERENCES:
patent: 6645493 (2003-11-01), Bucala et al.
patent: 0 162 812 (1985-11-01), None
Prusiner et al, PNAS 1993;90:10608-12.
Rondard et al, Biochemistry 1997;36:8954-61.
Janeway et al, Immunobiology 2001.
Lantz et al, Immunol 1975;29:301-6.
Goidl et al, Immunol 1975;29:629-41.
Doria et al, Immunol 1978;35:601-11.
Marchant et al, J Infect Disease 2006;193:1598-605.
Bozza, et al., “Targeted Disruption of Migration Inhibitory Factor Gene Reveals Its Critical Role in Sepsis”, J. Exp. Med., The Rockefeller University Press, vol. 189, No. 2, Jan. 18, 1999, pp. 341-346.
Declerck, et al., “Generation of Monoclonal antibodies against Autologous Proteins in Gene-inactivated Mice”, The Journal of Biological Chemistry, vol. 270, No. 16, Apr. 14, 1995, pp. 8397-8400.
Steinhoff, et al., “Evidence for a role of macrophage migration inhibitory factor in psoriatic skin disease”, British Journal of Dermatology, 1991, 141, pp. 1061-1066.
Donnelly, et al., “Regulatory role for microphage migration inhibitory factor in acute respiratory distress syndrome”, Nature Medicine, vol. 3, No. 3, Mar. 1997.
Calandra, et al., “Protection from septic shock by neutralizatoin of microphage migration inhibotory factor”, Nature Medicine, vol. 6, No. 2, Feb. 2000.
Calandra, et al., Macrophage Migration Inhibitory Factor: a Counter-Regulator of Glucocorticold Action and Critical Mediator of Septic Shock, Journal of Inflammmation, vol. 47, pp. 39-51 (1996).
Lan, et al., “The Pathogenic Role of Macrophage Migration Inhibitory Factor in Immunologically Induced Kidney Disease in the Rat”, J. Exp. Med., vol. 185, No. 8, Apr. 21, 1997, The Rockefeller University Press.
Leech, et al., “Macrophage Migration Inhibitory Factor in Rheumatoid Arthritis”, Arthritis & Rheumatism, vol. 42, No. 8, Aug. 1999, pp. 1601-1608.
Mitchell, Sustained Mitogen-activated Protein Kinase (MAPK) and Cytoplasmic Phospholipase A2 Activation by Macrophage Migration Inhibitory Factor (MIF), The Journal of Biological Chemistry, vol. 274, No. 25, Issue of Jun. 18, 1999, pp. 18100-18106.
Shimizu, et al., “High Expression of Macrophage Migration Inhibitory Factor in Human Melanoma Cells and Its Role in Tumor Cell Growth and Angiogenesis”, Biochemical and Biophysical Research Communications, vol. 264, 1999, pp. 751-758.
Mitamura, et al., Macrophage Migration Inhibitory Factor Levels in the Vitreous of Patients with Proliferative Vitreoretinopathy, American Journal of Ophthalmology, Dec. 1999, pp. 763-765.
Onodera, et al., “Macrophage Migration Inhiitory Factor Up-regulates Expression of Matrix Metalloproteinases in Synovial Fibroblasts of Rheumatoid Arthritis”, the Journal of Biological Chemistry, vol. 275, No. 1, Jan. 7, 2000, pp. 444-450.
Winter, et al., “antibody-based therapy XP-001005438 Humanized antibodies”, Immunology today, vol. 14, No. 6, 1993, pp. 243-246.
Heiman, et al., “New Steroidal anti-inflammatory antedrugs bind to macrophage glucocorticoid receptors and inhiit nitric oxide generation”, Steroids, 1998, vol. 63, Dec. 1998, pp. 644-649.
Borghesi et al., “Autologous anti-idiotypic antibody response is regulated by the level of circulating complementary idiotype,” Immunology, Blackwell Science Ltd., p. 172-177, (1996).
Pearson, Nature 2002; 415;8-9.
Humpherys et al, Science 2001; 293:95-97.
Yanagimachi, Mol Cell Endocrinol 2002; 187:241-8.
Wall et al, J Dairy Sci 1997; 80:2213-24.
Denning, Nat Biotech 2001; 19:559-562.
Houdebine, J. Biotech. 1994 vol. 34.
Bozza et al, Genomics 1995;27: 412-9.
Moreadith et al., J. Mol. Med. 1997; 75:208-16.
Pera et al, Journal of Cell Science 113: 5-10 (2000).
Mullins et al (1996) J. Clin. Invest. 98, p. S39.
Liao et al., “Adhesion-dependent signaling by Macrophage migration inhibitory factor (MIF),” J. Biol. Chem., vol. 278 (No. 1), p. 76-81, 2003.
Hanna Nabil
Kloetzer William S
Biogen Idec Inc.
Li Q. Janice
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
Method for preparing anti-MIF antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preparing anti-MIF antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preparing anti-MIF antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3871759